国家: 加拿大
语言: 英文
来源: Health Canada
METHOTREXATE (METHOTREXATE SODIUM)
UMAN PHARMA INC
L01BA01
METHOTREXATE
25MG
SOLUTION
METHOTREXATE (METHOTREXATE SODIUM) 25MG
INTRA-ARTERIAL
2ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0107545002; AHFS:
APPROVED
2009-09-16
_PRODUCT MONOGRAPH; Methotrexate Injection BP – Uman Pharma Inc. _ _Page 1 of 43_ _ _ PRODUCT MONOGRAPH PR METHOTREXATE INJECTION, BP 25 MG/ML Sterile Antimetabolite and Antirheumatic Uman Pharma Inc. Date of Preparation: September 2, 2009 100, boul. de l’Industrie Candiac, QC, J5R 1J1 Canada Control No. 132325 _PRODUCT MONOGRAPH; Methotrexate Injection BP – Uman Pharma Inc. _ _Page 2 of 43_ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................ 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 4 WARNINGS AND PRECAUTIONS ....................................................................................... 5 ADVERSE REACTIONS ....................................................................................................... 12 DRUG INTERACTIONS ........................................................................................................ 14 DOSAGE AND ADMINISTRATION .................................................................................... 17 OVERDOSAGE ...................................................................................................................... 26 ACTION AND CLINICAL PHARMACOLOGY ................................................................ 27 STORAGE AND STABILITY ............................................................................................... 29 SPECIAL HANDLING INSTRUCTIONS ........................................................................... 29 DOSAGE FORMS, COMPOSITION AND PACKAGING ................................................ 30 PART II: SCIENTIFIC INFORMATION ............................................................................... 31 PHARMACEUTICAL INFORMATION . 阅读完整的文件